EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination

Sitti Nurisyah, Mitsuhiro Iyori, Ammar A Hasyim, Khaeriah Amru, Kei Itani, Kurumi Nakamura, Kartika H Zainal, Handayani Halik, Irawaty Djaharuddin, Agussalim Bukhari, Puji Bs Asih, Din Syafruddin und 3 weitere

Narra J · 2025

DOI: 10.52225/narra.v5i1.1250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Narra J, 2025. Verfasst von Sitti Nurisyah und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Respiratory Medicine, Universitas Hasanuddin, Makassar, Indonesia. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evaluating long-term immunity after COVID-19 infection and vaccination is critical for managing potential outbreaks. The aim of this study was to develop a cost-effective in-house enzyme-linked immunosorbent assay (ELISA) based on Escherichia coli-expressed SARS-CoV-2 spike protein (E-S1) for antibody detection and to evaluate its performance. The system was validated by comparing the in-house ELISA results with those obtained using a commercial ELISA with HEK293-expressed spike protein (H-S1). Recombinant SARS-CoV-2 spike protein was produced in E. coli, purified, and validated for antigenicity via ELISA. Indirect ELISAs with both E-S1 and H-S1 antigens were performed on 386 serum samples from COVID-19 survivors, vaccinated individuals, and pre-pandemic controls collected at different time points. The E-S1 ELISA showed a statistically significant but weak correlation with H-S1 ELISA across all samples (r=0.205; p=0.0001). Stronger correlations were observed among vaccinated individuals with prior infection on day 90 (r=0.6017; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusCOVID-19Antibodies, ViralSARS-CoV-2COVID-19 VaccinesCOVID-19 Serological TestingHumansEnzyme-Linked Immunosorbent AssayEscherichia coliFemaleMaleMiddle AgedVaccinationAdult

Stichwörter der Autor:innen

COVID-19Capture antigenE. coli expression systemELISAantibody detection

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Pulmonology and Respiratory Medicine, Universitas Hasanuddin, Makassar, Indonesia.
  • Dr. Tadjuddin Chalid Hospital, Makassar, Indonesia.
  • Research Institute of Pharmaceutical Science, Musashino University, Nishitokyo, Japan.
  • Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Ishikawa, Japan.
  • Department of Medical Education, Universitas Hasanuddin, Makassar, Indonesia.
  • Universitas Megarezky, Makassar, Indonesia.

Zitieren

APA

Nurisyah, S., Iyori, M., Hasyim, A. A., Amru, K., Itani, K., Nakamura, K., Zainal, K. H., Halik, H., Djaharuddin, I., Bukhari, A., Asih, P. B., Syafruddin, D., Yoshida, S., Idris, I., & Yusuf, Y. (2025). Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination. Narra J. https://doi.org/10.52225/narra.v5i1.1250

Vancouver

Nurisyah S, Iyori M, Hasyim AA, Amru K, Itani K, Nakamura K, et al. Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination. Narra J. 2025. doi:10.52225/narra.v5i1.1250

BibTeX
@article{Nurisyah2025,
  author = {Nurisyah, Sitti and Iyori, Mitsuhiro and Hasyim, Ammar A and Amru, Khaeriah and Itani, Kei and Nakamura, Kurumi and Zainal, Kartika H and Halik, Handayani and Djaharuddin, Irawaty and Bukhari, Agussalim and Asih, Puji Bs and Syafruddin, Din and Yoshida, Shigeto and Idris, Irfan and Yusuf, Yenni},
  title = {Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination},
  journal = {Narra J},
  year = {2025},
  doi = {10.52225/narra.v5i1.1250}
}
Kostenlos starten →